Details

Autor(en) / Beteiligte

• Halpin, David M G
• Singh, Dave
• Hadfield, Ruth M

Titel

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective

Ist Teil von

• The European respiratory journal, 2020-05, Vol.55 (5), p.2001009

Ort / Verlag

England: European Respiratory Society

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• The current coronavirus 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection, raises important questions as to whether pre-morbid use or continued administration of inhaled corticosteroids (ICS) affects the outcomes of acute respiratory infections due to coronavirus. Many physicians are concerned about whether individuals positive for SARS-CoV-2 and taking ICS should continue them or stop them, given that ICS are often regarded as immunosuppressive. A number of key questions arise. Are people with asthma or COPD at increased risk of developing COVID-19? Do ICS modify this risk, either increasing or decreasing it? Do ICS influence the clinical course of COVID-19? (figure 1). Whether ICS modify the risk of developing COVID-19 or the clinical course of COVID-19 in people who do not have lung disease should also be considered (figure 1). There is no evidence on benefits or harms of inhaled steroids in COVID-19. It is essential that epidemiological studies of COVID-19 include detailed information on comorbidities and prior medication to help answer this question. https://bit.ly/2XVwIsa